Research Presentation Guidelines

• Full Completed Manuscripts Only: Submissions must consist of complete, finished manuscripts containing full datasets, results, and discussions. Standalone abstracts, study proposals, protocols, or preliminary works are strictly ineligible.

• Eligible Study Types: All study types are accepted (e.g., randomized controlled trials, observational studies, systematic reviews/meta-analyses, diagnostic accuracy studies, surgical techniques, and case reports/series) in all areas of ORL-HNS.

• Philippine Residents’ Case Reports: In compliance with society rules, case reports submitted by residents of ORL-HNS training institutions in the Philippines must first be submitted to the PSO-HNS Interesting Case Contest. Only those not accepted in that contest may be submitted for the Congress Free Paper session.

• Authorship & Declaration: The presenter must be one of the listed authors of the paper and must complete and submit the official Authorship Declaration Form included in the online submission portal.

• Originality & Prior Presentation Policy:

  • Work must be original and not published (e.g. journal, congress book, etc.), accepted, or under active peer review elsewhere prior to this submission.

  • Internal presentations at the investigator’s home institution or local hospital meetings are allowed.

• Congress Registration: The designated presenting author must be fully registered as a congress delegate by February 28, 2027. He/she shall then be eligible for the extended early bird registration rate.

• Editorial Rights: The scientific committee reserves the right to edit submitted abstracts for grammar and clarity.

• Finality: All decisions of the Scientific Committee and Board of Judges are final and binding.

All submissions must adhere strictly to the following manuscript formatting standards.

• Document Layout: Submissions must be in one (1) Microsoft Word (.docx) document, A4 page setup, Times New Roman font size 12, double-spaced throughout, with 1-inch (25.4 mm) margins on all sides.

• Page & Reference Limits: Maximum of 20 pages for original article main text.

• Order of Manuscript Sections:

  • Title Page: Informative and concise Title (in Title Case, under 150 characters), author names and credentials, institutional affiliations, presenting/corresponding author contact details, funding/disclosures, and total table/figure counts.

  • Structured Abstract & Keywords:

    • Word Count: Maximum of 500 words.

    • Headings:

      • Objective: Purpose and study hypothesis.

      • Methods: Study design, setting (multicenter, tertiary public/private), subjects/population (selection, sample size, randomization, masking), and ethical approvals.

      • Results: Main outcome measures with exact numerical data, absolute values, 95% confidence intervals, and statistical significance.

      • Conclusions: Direct, data-supported inferences.

      • Clinical Trial Registration Number: If applicable.

    • Keywords: 3 to 10 Medical Subject Headings (MeSH) terms.

  • Main Text:

    • Introduction: Background, research gap, hypothesis, and rationale (without heading).

    • Methods: Detailed design, setting, participants, interventions/devices (with manufacturer name and location in parentheses), and statistical software/tests.

    • Results: Logical narrative avoiding duplication with tables/graphs. Present absolute numbers alongside percentages; limit numeric values to 2 decimal places.

    • Discussion: Interpretation of findings, pathophysiologic explanations, literature comparison, limitations, and data-supported conclusions at the end (without a separate heading).

  • Acknowledgements: Non-author contributors (technical, statistical, writing support with permissions), study sponsors, and explicit AI use disclosures.

  • References: Vancouver style, cited sequentially in the text using Arabic numerical superscripts (e.g., ¹,²). End references numbered in order of appearance.

  • Tables: Double-spaced on separate pages (not embedded in text), numbered consecutively with brief titles, and footnotes using standard symbols (*, †, ‡, §, ‖, ¶, **).

  • Figure Legends & Figures: Figure legends typed on a separate page. (Diagnostic images must specify modality and view; histopathology must specify stain and magnification).

• Session Track Allocation: The Scientific Committee reserves the right to accept submissions as Oral Free Papers based on merit and program capacity.

Manuscripts must follow the appropriate EQUATOR Network reporting guideline checklists based on study design:

• Mandatory Ethics Document Upload: Authors must include in the submitted Microsoft Word document an image copy of their formal Institutional Review Board (IRB) / Research Ethics Committee (REC) approval letter or certificate of exemption during the submission process.

• Declaration of Helsinki: Clinical studies must confirm compliance with the Declaration of Helsinki (2013 revision). Animal studies must confirm adherence to laboratory animal care guidelines.

• Clinical Trial Registration: Prospective intervention trials must be registered in the Philippine Health Research Registry (PHRR), ClinicalTrials.gov, or any primary WHO ICTRP registry at or before first patient enrolment.

• Patient Privacy: De-identify all patient information. Mask facial photographs (unless accompanied by written informed consent) and remove all hospital numbers and identifying markers from radiographs.

• Authorship Restriction: AI chatbots and Large Language Models (e.g., ChatGPT, Claude, Gemini) cannot be listed as authors. Human authors retain full responsibility for content integrity, originality, and data validity.

• Mandatory AI Disclosure: Authors must disclose any use of generative AI in both the submission cover letter and Acknowledgements section, specifying the software tool, developer, version, date of use, and exact scope of application. (Spelling and grammar tools are exempt).

• Prohibited Practices: De novo manuscript generation without human oversight, unvalidated AI-generated data analysis code, citing AI as a primary reference source, and AI image manipulation/fabrication are strictly prohibited.

• Intellectual Property & Ownership: Authors retain full copyright and ownership of their research; presentation does not restrict subsequent publication in peer-reviewed journals outside of the congress.

• Confidentiality: Submissions are strictly confidential and accessible only to the Scientific Committee and designated reviewers.

• File Deletion Policy: To protect intellectual property and data privacy, all submitted manuscripts and uploaded documents will be permanently deleted from congress repositories after the event, retaining only accepted abstracts and necessary delegate records for official proceedings.

Accepted papers will be assigned to competitive podium slots during the congress (April 8–10, 2027).

1. Call for Manuscripts & 1st Announcement2nd week of September 2026
2. Opening of Online Submission PortalSeptember 16, 2026
3. Deadline for Full Manuscript SubmissionJanuary 8, 2027
4. Notification of Acceptance (Oral Free Paper / Poster)February 8, 2027
5. Presenter Early Bird Registration DeadlineFebruary 28, 2027
6. Congress Presentation DatesApril 8–10, 2027